Drug Pipeline

64Cu-SAR-bisPSMA Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
2
Phase 3
1
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-15 NCT06970847
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With…		 overall status: "Recruiting" → "Active Not Recruiting"
2026-05-15 NCT06970847
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With…		 Trial sites reduced: 28 -> 22 locations
2026-05-15 NCT06056830
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk…		 Trial sites expanded: 28 -> 31 locations
Active Studies by Phase
Phase 3
2
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06056830 Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk… Prostate Cancer Recruiting
NCT06970847 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With… Prostate Cancer Active, Not Recruiting
Phase 1/2
NCT04868604 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing… Prostatic Neoplasms, Castration-Resistant Recruiting
Sponsors Running 64Cu-SAR-bisPSMA Trials
Clarity Pharmaceuticals Ltd (3)
Disease Areas
Prostate Cancer (2)
Get alerts when 64Cu-SAR-bisPSMA trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free